Federal regulators intensify healthcare oversight as FTC launches Healthcare Task Force and strikes $7B insulin pricing deal with CVS
A significant shift in federal healthcare oversight is emerging, marked by aggressive regulatory intervention in drug pricing and industry practices.
No single number captures it — the story is in the connections.
The FTC's launch of a cross-agency Healthcare Task Force, coupled with its landmark settlement with CVS over insulin pricing manipulation, signals a new era of coordinated enforcement. This regulatory activism extends beyond pharmaceuticals, with CMS piloting new programs for complex pediatric care and considering automatic Medicare Advantage enrollment. Meanwhile, technological challenges are mounting, particularly in healthcare AI security, as new research reveals radiolog…
One pattern. Trace it.
- 01
A pattern worth naming
Watch for: 1) Additional FTC enforcement actions against other major PBMs within 60 days; 2) CMS release of specific eligibility criteria for the pediatric complex care pilot within 45 days; 3) Development of AI image authentication standards by major radiology associations within 90 days; 4) Healthcare Task Force's first major investigation announcement, likely targeting either hospital pricing or pharmacy benefit managers within 60 days.
Ask your CFO whether the unit economics on every new service line still pencil under the new rate environment.
By Joseph Lancaster, Editor — with research from Pine Needle's intelligence layer.
The next argument lands tomorrow at 6 a.m. Pacific. Get it in your inbox →